EARLYBIRD PARTICIPATES IN OVIVA’S $21M FINANCING ROUND TO ROLL OUT DIGITAL DIABETS TREATMENT ACROSS EUROPE

- Oviva’s Series B is led by MTIP with the participation of Earlybird alongside existing investors
- The company’s mission is to serve millions of people that suffer from type 2 diabetes by offering a personalised digital solution

Altendorf, Switzerland, 15th January 2020 – Oviva, the leading digital provider of type 2 diabetes treatment in Europe, has raised $21m in Series B funding. MTIP led the round, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech also participated.

The new capital will be used to further develop Oviva’s technology and expand across Europe to serve the millions of patients not accessing treatment today. It brings the total amount raised by Oviva to-date to $34m.

Globally, an average of one in eleven people has been diagnosed with diabetes – nearly double the proportion recorded in 1980. In Europe, 50% of the population is overweight and at higher risk of developing Type 2 diabetes. Oviva offers an evidence-based digital solution to stop the progression of and reverse Type 2 diabetes and obesity-related conditions. Patients receive tailored nutrition advice and personalised coaching comfortably via phone and so Oviva’s technology-supported treatment has consistently demonstrated higher patient uptake, retention and outcomes at lower costs compared to face-to-face therapy. Oviva has treated 90,000 patients to-date across the UK, Germany, France, Switzerland and the UAE, consistently doubling each year for the last three years.

Lucy Jones, Clinical Director of Oviva commented: “Behaviour change is the safest and most cost-effective way of preventing and managing diet related health conditions including Type 2 diabetes. Our technology empowers patients to take a leading role in managing their health and improves compliance and outcomes.”

Kai Eberhardt, CEO and Co-founder of Oviva added: “The new financing allows us roll out our uniquely effective solution to large patient populations rapidly across Europe and further develop the underlying technology to better address patients’ unmet needs.”

Christoph Kausch, CEO of MTIP commented: “Oviva is a superb example of a digital health company with the potential to transform the lives of millions of people across the globe for the better. We are excited to become partners in their mission to improve access to effective diabetes- and obesity-management solutions with the next phase of the company’s growth.”

“Oviva’s digital offering is based on sound clinical validation and brings significant benefit to patients - without undesired side effects,” stated Rainer Christine, partner of Earlybird, on their newest investment. “The addressable market is very large, and we believe that Oviva is in an excellent position to become a category leader in digital therapy. We are very excited to now be part of this endeavour.”

Christoph Kausch from MTIP and Rainer Christine from Earlybird will be joining Oviva’s Board of Directors.
About Oviva

Oviva was founded 2014 by an interdisciplinary team from medicine and technology who saw the challenges patients experienced accessing tailored and effective treatment as mandated by national guidelines. Globally, an average of one in eleven people has been diagnosed with diabetes – nearly double the proportion in 1980. In Europe, 50% of the population is overweight and at higher risk of developing Type 2 diabetes. The technology incorporated in Oviva’s treatment strengthens the relationship between patients and professional care providers, improves patient access and reduces costs, as demonstrated by Oviva’s results and 6 peer-reviewed publications to date. The technology allows patients to self-record their food intake, weight, activity and symptoms, educate themselves about their disease and healthy behaviours, and communicate with other patients and their care provider. This ensures patients receive personalised support without the hassle of face-to-face appointments.

More information on www.oviva.com

About Earlybird:

Earlybird is a venture capital investor focused on European technology companies. Founded in 1997, Earlybird invests in all growth and development phases of a company. Amongst the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support as well as access to an international network and capital markets. Earlybird manages separate funds focussing on digital technologies in Eastern and Western Europe as well as healthcare across Europe. With over EUR 1 billion under management, seven IPOs and 24 trade sales, Earlybird is one of the most successful venture capital firms in Europe.


Press Contact
Earlybird

Catrin Schmidt
+49 30 46 72 47020
press@earlybird.com

Press Contact
Oviva AG

Kai Eberhardt
+41 41 511 52 41
kai@oviva.com